Explore ViiV Healthcare

I am a
  • HCP
  • person living with HIV
  • NGO or patient group
  • job seeker
  • member of the public
  • academia / entrepreneur
  • media
...looking for
  • information about VHC medicines
  • clinical data and insights on VHC medicines
  • Independent Medical Education
  • medicines in development
  • how VHC is advancing HIV treatment and care
...looking for
  • information about VHC medicines
  • information and support about living with HIV
  • how to report a side effect
  • news and stories from ViiV Healthcare
...looking for
  • funding / grants
  • ViiV Healthcare's approach to partnerships
  • how ViiV Healthcare works with NGOs
  • news and stories from ViiV Healthcare
  • connect with ViiV Healthcare's community
...looking for
  • job opportunities
  • information about ViiV Healthcare
  • ViiV Healthcare's office locations
  • news and stories from ViiV Healthcare
...looking for
  • who are ViiV Healthcare
  • corporate ethics & compliance
  • news and stories from ViiV Healthcare
...looking for
  • opportunities to partner with ViiV Healthcare
  • information on ViiV Healthcare's Innovation Unit
  • news and stories from ViiV Healthcare
...looking for
  • press releases
  • ViiV Healthcare's Leadership
  • news and stories from ViiV Healthcare

CABENUVA

Cabenuva (cabotegravir/rilprivirine) is listed on the Australian Register of Therapeutic Goods (ARTG).

CABENUVA is used to treat Human Immunodeficiency Virus (HIV) infection in adults aged 18 years and over. CABENUVA is a complete, long-acting regimen administered every 2-months and contains two medicines, cabotegravir prolonged-release suspension for injection and rilpivirine prolonged release suspension for injection, packaged together.

CABENUVA does not cure HIV infection; it keeps the amount of virus in your body at a low level.

Resources

For patients:

For HCPs:

Date of Preparation: February 2021. PM-AU-CBR-WCNT-210001